Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound according to formula (1):

$$R_2O_2S$$
 A_1
 N
 $CH_2)_{\overline{n}}$
 R_1

Wherein Het represents an optionally substituted heterocyclic group selected from the group consisting of oxetane, furan, dihydrofuran; tetrahydrofuran; pyran; dihydropyran; tetrahydropyran; dioxole; thiophene; dihydrothiophene; tetrahydrothiophene; thiopyran; dihydrothiopyran; tetrahydrothiopyran; pyrrole; dihydropyrrole; pyrrolidine; pyridine; dihydropyridine; tetrahydropyridine; pyrazole; 2-pyrazoline; pyrazolidine; piperidine; pyrazole; 2-pyrazoline; pyrazolidine; imidazole; imidazolidine; pyrimidine; pyrazine; oxazoline; piperazine; 1,2,3-triazole; 1,2,4-triazole; tetrazole; isoxazole; 1,3-oxadiazole; 1,2,3-oxadiazole; 1,2,t-thiazole; 1,3-thiazole; 1,2,3-thiadiazole; 1,2,4-thiadiazole;

- 3 -

Appln. No. 10/674,488 Amd. dated August 12, 2004 Reply to Office Action of May 27, 2004

1,2,5-thiadiazole; 1,3,4-thiadiazole; 1,3-dioxolan, oxazolidine, and morpholine;

Wherein one of A1 and A2 represents [[-CH+]] $\underline{-CH}$ and the other of A1 and A2 presents [[-N-]] $\underline{-N}$;

A3 represents -CH2-, -(C=0)-, or -SO2-;

R1 represents a group selected from the following formulae:

Wherein A4 represents -O-, -S-, or -NH-;

R2 represents a straight or branched alkyl group having 1 to 3 carbon atoms;

n is 0, 1, or 2;

Or <u>an</u> addition <u>salts</u> <u>salt</u> thereof with a pharmaceutically acceptable acid or base, or <u>hydrates</u> <u>hydrate</u> thereof.

Claims 2-3. (Cancelled).

4. (Original) The compound according to claim 3 wherein Het is an optionally substituted group selected from the group consisting of furan; 1,3-thiazole; 1,3-oxazole;

Appln. No. 10/674,488 Amd. dated August 12, 2004 Reply to Office Action of May 27, 2004

1,3,4-oxadiazole; pyridine; pyrimidine; and 5,6-dihydropyran; or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.

- 5. (Original) The compound according to claim 1 wherein Het is substituted with a carboxyl group; or a nitrogen atom of the nitrogen atom-containing heterocyclic group of Het is N-oxide; or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.
- 6. (Original) The compound according to claim 1 wherein n is 0 or 1; or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.
- 7. (Currently Amended) The compound according to claim 1 wherein Al is -CH=; or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.
- 8. (Currently Amended) The compound according to claim 1 wherein the group R1-A3- is a 4-fluorobenzyl group; or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.
- 9. (Original) A compound selected from the group consisting of:

2-(2-furyl)-1-(4-fluorobenzyl)-5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridine;

```
1-(4-fluorobenzyl)-2-(oxazol-2-yl)-5-
methanesulfonyl-1H-pyrrolo [2,3-b]pyridine;
5-methanesulfonyl-2-(2-pyridyl)-1-(4-fluorobenzyl)-
1H-pyrrolo[2,3-b]pyridine;
1-(4-fluorobenzyl)-5-methanesulfonyl-1-(2-
pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine;
2-(2-furanyl)-5-methanesulfonyl-1-(2-pyridylmethyl)-
1H-pyrrolo[2,3-b]pyridine;
1-(4-fluorobenzyl)-5-methanesulfonyl-2-(5-
methylfuran-2-yl)-1H-pyrrolo[2,3-b]pyridine;
2-(2-furanyl)-1-cyclohexylmethyl-5-methanesulfonyl-
1H-pyrrolo[2,3-b]pyridine;
5-methanesulfonyl-2-(1-oxy-2-pyridyl)-1-(4-
fluorobenzyl)-1H-pyrrolo[2,3-b]pyridine;
6-[1-(4-fluorobenzyl)-5-methanesulfonyl-1H-
pyrrolo[2,3-b]pyridin-2-yl] nicotinic acid
methylamide;
1-(4-fluorobenzyl)-5-methanesulfonyl-2-
([1,3,4]oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridine;
1-(4-fluorobenzyl)-5-methanesulfonyl-2-(5-
fluoropyrimidin-4-yl)-1H-pyrrolo [2,3-b]pyridine;
1-(2,4-difluorobenzyl)-5-methanesulfonyl-2-
[(1,3,4) \text{ oxadiazol-}2-yl]-1H-pyrrolo[2,3-b]pyridine;
```

Appln. No. 10/674,488 Amd. dated August 12, 2004 Reply to Office Action of May 27, 2004

and addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.

- 10. (Original) The compound according to claim 1 wherein R1 is phenyl, pyridine, or cyclohexyl and Het is furan, thiazole, oxazole, osadiazole, pyrimidine, pyran, or triazole.
- 11. (Original) A pharmaceutical composition containing as the active ingredient a compound according to claim 1 with a pharmaceutically acceptable ingredient.
- 12. (Original) A method for inhibiting cyclooxygenase-2 in a patient in need thereof comprising administering to said patient an effective amount of a compound according to claim 1.
- 13. (Original) A method for treating inflammation induced by cyclooxygenase-2 in a patient in need thereof comprising administering to said patient an effective amount of a compound according to claim 1.

- 7 -